Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Procarbazine
Drug ID BADD_D01846
Description An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
Indications and Usage For use with other anticancer drugs for the treatment of stage III and stage IV Hodgkin's disease.
Marketing Status approved; investigational
ATC Code L01XB01
DrugBank ID DB01168
KEGG ID D08423
MeSH ID D011344
PubChem ID 4915
TTD Drug ID D08GYO
NDC Product Code Not Available
UNII 35S93Y190K
Synonyms Procarbazine | Procarbazine Monohydrobromide | Monohydrobromide, Procarbazine | Procarbazine Hydrochloride | Hydrochloride, Procarbazine | Procarbazine Monohydrochloride | Monohydrochloride, Procarbazine | Matulane | Natulan
Chemical Information
Molecular Formula C12H19N3O
CAS Registry Number 671-16-9
SMILES CC(C)NC(=O)C1=CC=C(C=C1)CNNC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.0020.001175%Not Available
Thrombosis24.01.01.006--Not Available
Toxic epidermal necrolysis12.03.01.015; 23.03.01.008; 11.07.01.006; 10.01.01.006--
Tremor17.01.06.002--
Urticaria23.04.02.001; 10.01.06.0010.004623%
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vomiting07.01.07.0030.006716%
Cardiotoxicity02.11.01.009; 12.03.01.007--Not Available
Hypoacusis04.02.01.006--
Balance disorder17.02.02.007; 08.01.03.0810.000381%Not Available
Lung cancer metastatic22.08.01.004; 16.19.02.003--Not Available
Malignant neoplasm progression16.16.01.0050.000392%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Type IV hypersensitivity reaction10.01.03.022--Not Available
Haemorrhage24.07.01.002--Not Available
Lung neoplasm malignant22.08.01.001; 16.19.02.001--Not Available
Cardiac disorder02.11.01.0030.000358%Not Available
Metastatic neoplasm16.16.01.007--Not Available
Neoplasm progression16.16.02.0050.000414%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.004108%
Adverse drug reaction08.06.01.0090.000761%Not Available
Disease progression08.01.03.0380.002798%
Pulmonary toxicity22.01.02.007; 12.03.01.013--Not Available
Haemorrhagic diathesis24.07.01.020; 01.01.03.003--Not Available
Brain neoplasm malignant16.30.04.002; 17.20.04.0020.000112%Not Available
The 5th Page    First    Pre   5    Total 5 Pages